Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ayala Pharmaceuticals Inc (PK) | ADXS | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.256 | 05:33:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.256 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.135 - 1.95 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.256 | USD |
Ayala Pharmaceuticals Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.63M | 4.84M | 1.80M | 13k | -48.07M | -9.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ayala Pharmaceuticals (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/06/2024 | 06:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 3/05/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/05/2024 | 07:16 | Edgar (US Regulatory) | Form DEFM14C - Definitive information statement relating to.. |
| 2/23/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 16:22 | Edgar (US Regulatory) | Form PREM14C - Preliminary information statements relating.. |
| 2/14/2024 | 15:26 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/12/2024 | 13:16 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/12/2024 | 10:58 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/12/2024 | 07:27 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/09/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/06/2024 | 07:51 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/03/2024 | 15:18 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADXS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.2844 | 0.3196 | 0.20 | 0.2725424 | 15,512 | -0.0284 | -9.99% |
| 1 Month | 0.55 | 0.625 | 0.135 | 0.3181731 | 20,362 | -0.294 | -53.45% |
| 3 Months | 0.769 | 0.77 | 0.135 | 0.4336999 | 10,496 | -0.513 | -66.71% |
| 6 Months | 0.80 | 1.49 | 0.135 | 0.8022834 | 17,667 | -0.544 | -68.00% |
| 1 Year | 1.245 | 1.95 | 0.135 | 0.8563588 | 11,309 | -0.989 | -79.44% |
| 3 Years | 0.158 | 4.50 | 0.0514 | 0.1761335 | 181,501 | 0.098 | 62.03% |
| 5 Years | 0.158 | 4.50 | 0.0514 | 0.1761335 | 181,501 | 0.098 | 62.03% |
Ayala Pharmaceuticals (PK) Description
| Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors. |
